| tocilizumab | Genentech, Inc. | ||
| 80mg/4mL, 200mg/10mL, 400mg/20mL; Injection, Intravenous |
More Than $1000 mn
|
||
| None |
Less Than 5
|
||
| None | None | ||
|
Less Than 5
|
Less Than 5
|
||
| ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor indicated for treatment of Rheumatoid Arthritis : Adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. | |||
|
Yes
| |||
| Actemra | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | Patent 32 | Patent 33 | Patent 34 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ****** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* |
| **** ******* ************ **** ************ *** ******* *** *********** ********** | ************** ************ ****-**-* ******** ******** *** ********* ** ******** ********** ********* | ****** *** ********** *** ******** ********** **** ** ********** ***** | ****** *** *** ********** ** * ************ ************** | ****** *** ********* * *********** ********** ****** ************ ********** ** *************** | ****** ** ******* ***** ********** ******** | **** ******* ************ **** ************ *** ******* *** *********** ********** | ****** *** ******** ********** ********* **** * ***** **-* ******** ******** *** ************ | **** ******* ************ **** ************ *** ******* *** *********** ********** | ************** ************ ****-**-* ******** ******** | ********** ** ******** ** *********-**** **** ******* ***** | **** ************* ********-********** ****** *********** | ****** *** *** ********** ** * ************ ************** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ****** *** ********** ** ******** | ****** *** *** ********** ** * ************ ************** | **** ************* ********-********** ****** *********** | ****** *** *** ********** ** * ************ ************** | **** ************* ********-********** ****** *********** | ****** ** ********* ******* | ******* *** ******** ***********-* ******* ******** | ******** ** ********* ******** ******* ***********-* ******** | ********** ** ******** ** *********-**** **** ******* ***** | **** ************* ********-********** ****** *********** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ************** ************ ****-**-* ******** ******** | ********* ** ********** **** **-* ********** | ****** *** ******** ********** ********* ** ************* ** ****-**-* ******** *** ************ | ******** ** ********* ******** ******* ***********-* ******** | ************** ************ ****-**-* ******** ******** *** ********* ** ******** ********* | ****** *** ********* * *********** ********** ****** ************ ********** ** *************** | ********** ** ******** ** *********-**** **** ******* ***** | ************** ************ ****-**-* ******** ******** | ******* *** ********* ******** ** ********* ******** ******* ***********-* ******** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | ******* | ******** | ******** ** *** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|